CHIR-265 is a benzimidazole derivative with substituents at positions 1, 2, and 5: methyl, [4-(trifluoromethyl)phenyl]amino, and {2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl}oxy groups. It inhibits RAF kinases, including the BRAF V600E mutant, and functions as an antineoplastic agent, apoptosis inducer, antiviral agent, EC 2.7.10.1 inhibitor, B-Raf inhibitor, and angiogenesis inhibitor. It is an aromatic ether, imidazole, pyridine, organofluorine compound, benzimidazole, substituted aniline, and (trifluoromethyl)benzene.
